What comes after PSA testing? In an @MedicalLabMLO article, Dr. Mark Stovsky, CMO at Cleveland Diagnostics, explores a comprehensive prostate cancer diagnostic pathway integrating ancillary testing, imaging, & biopsy to help guide the next step. hubs.la/Q04zQnRb0

False-positive cancer screening results can lead to anxiety, invasive procedures, & financial burdens. Dr. Jason Hafron discusses with @OncLive how tools like the IsoPSA Test can help inform next steps. hubs.la/Q04zXZHn0

“You cannot think of PSA as a destiny-driven measurement.” Dr. Tarik Benidir discusses navigating PSA, MRI, & ancillary tests like the IsoPSA Test on @_backtableUro: hubs.la/Q04zXZbf0 Listen to the full episode here: hubs.la/Q04zX-KX0 #ProstateCancer #Urology #PSA

We’re pleased to see MediaPost highlight our #PSAonPSA campaign. The article explores the campaign & how clinicians can make prostate health education more accessible: hubs.la/Q04yDS0w0

Thank you to everyone who watched the PSA on PSA series and downloaded and shared the factsheet this month. Your participation helped Cleveland Diagnostics support @ZEROCancer. The conversation continues at hubs.la/Q04xJ03y0. #PSAonPSA #MensHealth

Dr. John Oliffe, Dr. Jason Hafron, and Dr. Craig Rogers each weigh in on what needs rethinking in prostate cancer care. Visit hubs.la/Q04ydrFC0 and watch the Second: hubs.la/Q04ydrCG0 #PSAonPSA #ProstateCancer

It’s not too late. For every factsheet downloaded at hubs.la/Q04xHYK-0 this September, we will donate to @ZEROCancer. Learn more about prostate cancer risk, screening, and the questions worth asking your doctor. #PSAonPSA #ProstateCancerAwarenessMonth

This week on On Call for Men’s Health: A PSA on PSA, Dr. Michael Lutz and Dr. Craig Rogers talk about how prostate cancer care has evolved and how urologists can help patients navigate uncertainty. Watch now at hubs.la/Q04xHXj40. #PSAonPSA #Urology

Join Dr. Mark Stovsky at @AdMeTech's Global Prostate Cancer Summit (GPS 2026), where he'll present prospective clinical validation data evaluating the IsoPSA Assay alone and with mpMRI for detecting high-grade prostate cancer. Register: hubs.la/Q04qq_l40

Prostate cancer care involves much more than one test or one conversation. Which topic do you think deserves more attention?

Prostate cancer detection has changed a lot from the days when an elevated PSA often led straight to biopsy. Dr. Michael Lutz & Dr. @hafronjason on how tools like the IsoPSA Test help physicians better understand risk: hubs.la/Q04x88qW0 #IsoPSA #Urology

How can clinicians get a clear picture of patient risk? Dr. Soroush Rais-Bahrami spoke with @ThePathologist about how looking beyond PSA concentration can provide a clearer picture of prostate cancer risk. Read more: hubs.la/Q04vM6Ln0

In the first episode of On Call for Men’s Health: A PSA on PSA, Dr. Michael Lutz and Dr. John Oliffe talk about the mental health side of prostate cancer and why getting support should not wait for a crisis. Tune in at hubs.la/Q04wrlQs0. #PSAonPSA #MensHealth

Prostate Cancer Awareness Month is here, and so is our 4th annual PSA on PSA campaign.  Download the factsheet at hubs.la/Q04vBrPW0 & we’ll donate to @ZEROCancer. New episodes of On Call for Men’s Health: A PSA on PSA every week.  #PSAonPSA #ProstateCancerAwarenessMonth

A 62-year-old man had elevated PSA and a PI-RADS 3 lesion on mpMRI. His IsoPSA Test result was 4.2.  For his urologist, Dr. Arpeet Shah, this supported avoiding biopsy and continuing surveillance.  More case studies: hubs.la/Q04tNpNF0  #ProstateCancer #IsoPSA #Urology

How can the IsoPSA Test help bring greater clarity to prostate cancer risk assessment? Dr. @HafronJason discusses how combining the IsoPSA Test with mpMRI can help quantify the risk of csPCa, supporting more informed, shared decision-making.  Watch here: hubs.la/Q04tN9tB0

In @pathologistmag, Dr. Soroush Rais-Bahrami explores how ancillary tests could provide more clinically meaningful information from PSA. “A concentration-based test tells you that PSA is elevated…but a structure-based approach may help explain why.” hubs.la/Q04tDQXj0

mpMRI is a valuable tool in the diagnostic pathway for prostate cancer, but it is not without limitations. The IsoPSA Test can help clarify PI-RADS scores & provide insight when MRI is not an option. Discover how it can improve biopsy decisions: hubs.la/Q04skGpD0

What does the future of prostate cancer care look like? Dr. Jason Hafron shares why ancillary tests have the potential to help answer two critical questions: • Who needs treatment? • What's the best treatment for that patient? Watch the short video. ⬇️

As new evidence emerges, early detection of prostate cancer continues to evolve. Hear Dr. Badrinath Konety discuss key updates to the 2026 AUA/SUO Early Detection Guidelines, including MRI, ancillary tests, and shared decision-making. Watch here: hubs.ly/Q04qq-Mz0